A Vibrio cholerae serogroup O1 vaccine candidate against CTXETΦ infection

Vaccine

Volumn 25, Issue 20, 2007, Pages 4046-4055

  Yan, Meiying ^a   Liu, Guangwen ^a   Diao, Baowei ^a   Qiu, Haiyan ^a   Zhang, Lijuan ^a   Liang, Weili ^a   Gao, Shouyi ^a   Kan, Biao ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Immunity; Vaccine; Vibrio cholerae

Indexed keywords

CHOLERA TOXIN; CHOLERA VACCINE; RECOMBINANT VACCINE; RECOMBINANT VACCINE IEM109; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BACTERIOPHAGE; BIOTYPE; BLOOD GROUP TYPING; CHOLERA; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; GENE DELETION; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIBRIO CHOLERAE;

ANIMALS; ANTIBODIES, BACTERIAL; CHOLERA; CHOLERA VACCINES; CLONING, MOLECULAR; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTESTINES; RABBITS; VACCINES, SYNTHETIC; VIBRIO CHOLERAE O1;

EID: 34247327811     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.02.043     Document Type: Article

References (30)

1. Albert M.J., Siddique A.K., Islam M.S., Faruque A.S., Ansaruzzaman M., Faruque S.M., et al. Large outbreak of clinical cholera due to Vibrio cholerae non-O1 in Bangladesh. Lancet 341 (1993) 704
2. Marc P.G., Duncan S., Claire L.C., and Marie P.K. A review of vaccine research and development: human enteric infections. Vaccine 24 (2006) 2732-2750
3. Richard I.W. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries. Vaccine 23 (2005) 3369-3385
4. Kenner J.R., Coster T.S., Taylor D.N., Trofa A.F., Barrera-Oro M., Hyman F., et al. Peru-l 5, an improved live attenuated oral vaccine candidate for Vibrio cholerae Ol. J Infect Dis 172 (1995) 1126-1129
5. Kotloff K.L., Wasserman S.S., O'Dounad, Losonsky G.A., Cryz S.J., Levine M.M., et al. Safty and immumogenicity in North Americans of a single dose of live oral cholera vaccine CVD103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun 60 (1992) 4430-4432
6. Levine M.M., and Kaper J.B. Live oral cholera vaccines: from principle to product. Bull Inst Pasteur 93 (1995) 243-253
7. Taylor D.N., Killeen K.P., Hack D.C., Kenner J.R., Coster T.S., Beattie D.T., et al. Development of a live, oral, attenuated vaccine against El Tor cholera. J Infect Dis 170 (1994) 1518-1523
8. Tacket C.O., Kotloff K.L., Lonsonsky G., Nataro J.P., Michalski J., Kaper J.B., et al. Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111. Am J Trop Med Hyg 56 (1997) 533-537
9. Richie E.E., Punjabi N.H., Sidharta Y.Y., Peetosutan K.K., Sukandar M.M., Wasserman S.S., et al. Efficacy trial of single-dose live oral cholerav accine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 18 (2000) 2399-2410
10. Cohen M.B., Giannella R.A., Bean J., Taylor D.N., Parker S., Hoeper A., et al. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-l5: a live aftenuated oral cholera vaccine. Infect Immun 70 (2002) 1965-1970
11. Wei L., Karla J.F., Rebecca C., Jessica A.S., Marc B.R., Kerstin E.C., et al. Identification of a Vibrio cholerae RTX toxin gene cluster that is tightly linked to the cholera toxin prophage. Proc Natl Acad Sci USA 96 (1999) 1071-1076
12. Karla J.F., and John J.M. In vivo covalent cross-linking of cellular actin by the Vibrio cholerae RTX toxin. EMBO J 19 (2000) 5315-5323
13. Fullner K.J., Boucher J.C., Hanes M.A., Haines III G.K., Meehan B.M., Walchle C., et al. The contribution of accessory toxins of Vibrio cholerae O1 El Tor to the proinflammatory response in a murine pulmonary cholera model. J Exp Med 195 (2002) 1455-1462
14. Viret J.F., Dietrich G., and Favre D. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR. Vaccine 22 (2004) 2457-2469
15. Waldor M.K., and Mekalanos J.J. Lysogenic conversion by a filaemtous phage encoding cholera toxin. Science 272 (1996) 1910-1914
16. Ketley I.M., Kaper J.B., Herrington D.A., Losonsky C., and Levine M.M. Diminished immunogenicity of a recombination-deficient derivative of Vibrio cholerae vaccine strain CVD103. Infect Immun 58 (1990) 1481-1484
17. Liang W.L., Wang S.X., Yu F.G., Qi G.M., and Kan B. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate IEM108. Infect Immun 71 (2003) 5498-5504
18. Liu Y.Q., Qi G.M., Wang S.X., Yu Y.M., Duan G.C., Zhang L.J., et al. A natural vaccine candidate strain against cholera. Biomed Environ Sci 8 (1995) 350-358
19. Liu G.W., Yan M.Y., Liang W.L., Qi G.M., Liu Y.Q., Gao S.Y., et al. Resistance of the cholera vaccine candidate IEM108 against CTXΦ infection. Vaccine 24 (2006) 1749-1755
20. Kimsey H.H., and Waldor M.K. CTXΦ immunity: application in the development of cholera vaccines. Proc Natl Acad Sci USA 95 (1998) 7035-7039
21. Attridge S.R. Thymine auxotrophy as an attenuating marker in Vibrio cholerae. Microb Pathog 19 (1995) 11-18
22. Ryan E.T., Crean T.I., Kochi S.K., John M., Luciano A.A., Killeen K.P., et al. Development of a Delta glnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae. Infect Immun 68 (2000) 221-226
23. Valle E., Ledon T., Cedre B., Campos J., Valmaseda T., Rodriguez B., et al. Construction and characterization of a nonproliferative El Tor cholera vaccine candidate derived from strain 638. Infect Immun 68 (2000) 6411-6418
24. Terry D.C., Andrew J.M., and Randall K.H. A new mobilizable cosmid vector for use in Vibrio cholerae and other gram-negative bacteria. Gene 153 (1995) 85-87
25. Donnenberg M.S., and Kaper J.B. Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect Immun 59 (1991) 4310-4317
26. Maria R.F., Elisabetta M., Liu Y.Q., Qi G.M., Duan G.C., Rino R., et al. IEM101, a naturally attenuated Vibrio cholerae strain as carrier for genetically detoxified derivatives of cholera toxin. Vaccine 19 (2001) 75-85
27. Rubin E.J., Lin W., Mekalanos J.J., and Waldor M.K. Replication and integration of a Vibrio cholerae cryptic plasmid linked to the CTX prophage. Mol Microbiol 28 (1998) 1247-1254
28. Faruque S.M., Rahman M.M., Hasan A.K., Nair G.B., Mekalanos J.J., Sack D.A., et al. Diminished diarrheal response to Vibrio cholerae strains carrying the replicative form of the CTXΦ genome instead of CTXΦ lysogens in adult rabbits. Infect Immun 69 (2001) 6084-6090
29. Svennerholm A.M., and Holmgren J. Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect Immun 13 (1976) 735-740
30. Bondre V.P., Sinha V.B., and Srivastava B.S. Evaluation of different subcellular fractions of Vibrio cholerae O139 in protection to challenge in experimental cholera. FEMS Immunol Med Microbiol 19 (1998) 323-329